Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA approves Pfizer’s Cibinqo for adolescent atopic dermatitis

By Brian Buntz | February 10, 2023

PfizerPfizer (NYSE:PFE) has announced that the FDA has approved its supplemental New Drug Application (sNDA) for Cibinqo (abrocitinib) for moderate-to-severe atopic dermatitis. The approval expands the indication for the drug, which was previously only approved for adults with the skin condition in early 2022.

The expanded indication includes adolescents between the ages of 12 and 18 whose disease is not adequately controlled with other systemic drugs or when their use is inadvisable.

Cibinqo is a potential blockbuster

In 2020, Pfizer had estimated that abrocitinib would eventually garner $3 billion in peak annual sales.

The company is also investigating its potential in prurigo nodularis and pruritus.

The systemic JAK inhibitor is in the same class as baricitinib from Incyte and Lilly and upadacitinib from AbbVie.

The FDA updated the prescribing information for Cibinqo to include data from the JADE TEEN clinical trial, which evaluated the 100 mg and 200 mg doses of the drug versus placebo in adolescents. The randomized, double-blind, placebo-controlled trial enrolled 287 patients and assessed improvements in skin clearance, itch, disease extent and severity through various measures, including the Investigator Global Assessment (IGA), Peak Pruritus Numerical Rating Scale (PP-NRS), and Eczema Area and Severity Index (EASI).

The JADE TEEN study

The randomized, double-blind, placebo-controlled JADE TEEN trial assessed improvements in skin clearance, itch, disease extent and severity by evaluating various measures, including the Investigator Global Assessment (IGA), Peak Pruritus Numerical Rating Scale (PP-NRS) and Eczema Area and Severity Index (EASI).

The JADE TEEN study enrolled 287 patients.

The prescribing information for Cibnqo now includes data from five randomized, placebo-controlled clinical trials and a long-term extension study, involving more than 1,600 patients who received the medication.

The FDA label for the drug has a black box warning describing an increased risk of infection, major adverse cardiovascular events and malignancies. The warning is similar to those issued for other JAK inhibitors.

To date, the Cibingo trials have shown that the drug has a consistent safety profile and provides significant improvements in skin clearance, disease extent and severity, as well as rapid reduction in itching for some patients with atopic dermatitis. The most commonly reported adverse events among patients treated with Cibingo for up to 16 weeks include nasopharyngitis, nausea and headache, with the frequency ranging from 7.9% to 14.5% depending on the dose.


Filed Under: Dermatology
Tagged With: Cibinqo, Pfizer
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Takeda
TAK-279, an oral small-molecule TYK2 inhibitor offering the convenience of a once-daily pill and biologic-like clinical responses
AbbVie 770 logo
Upadacitinib shows promising results in ongoing phase 3 atopic dermatitis studies
plant under a microscope
Legacy Healthcare aims to upend alopecia areata treatment with a botanical drug
Sun Pharma
FDA places clinical hold on Sun Pharma’s dermatology drug as a result of blood clot risk
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE